Immunological Disorders and Immunotherapy
Open Access

A New Frontier in Cervical Cancer Treatment: Harnessing Non-Thermal Plasma for Fertility Preservation

Yujin Han^{* *}Correspondence: Yujin Han, Department of immuobiology, Kyung Hee University, Seoul, South Korea, Email:

Author info »

Description

For young women diagnosed with cervical cancer, the dual battle against a life-threatening disease and the potential loss of fertility is uniquely challenging. Conventional treatments such as radical hysterectomy and chemo radiotherapy offer excellent oncological outcomes but often come at the cost of reproductive capability. As societal trends increasingly delay childbearing into later years, there is a growing clinical imperative for non-surgical, fertility-preserving treatment strategies. One emerging solution may come from an unlikely source Non-Thermal Plasma (NTP), a technology that could revolutionize how early-stage cervical cancer is treated.

Biomarker guided non-invasive therapy offers hope for young women

Non-thermal plasma, a state of matter composed of Reactive Oxygen and Nitrogen Species (RONS), has already demonstrated powerful anti-cancer effects in a variety of malignancies, including cervical cancer. The sets NTP apart from other minimally invasive techniques like photodynamic therapy or high-intensity focused ultrasound is its unique ability to penetrate tissue and selectively induce cytotoxicity in cancer cells, while sparing healthy tissue. This characteristic, coupled with its capacity to stimulate immunogenic cell death, makes NTP a compelling candidate for localized, fertility-preserving therapies.

The study in focus takes this potential a step further by identifying Superoxide Dismutase 1 (SOD1) as a potential biomarker for NTP sensitivity. Through a detailed molecular investigation, researchers found that the expression levels of SOD1 correlated with how well cervical cancer cells responded to NTP. This insight is critical, as it allows for the possibility of stratifying patients offering the therapy to those most likely to benefit from it and avoiding unnecessary exposure for others.

Even more compelling is the discovery that the HPV oncoprotein E6 and the tumor suppressor gene p53 regulate the expression of SOD1. Since most cervical cancers are driven by high-risk HPV types, particularly HPV-16 and HPV-18, this upstream regulation provides a mechanistic explanation for the variability in NTP sensitivity and connects the therapy to the core biology of the disease.

NTP killing cancer

Beyond its direct cytotoxicity, NTP appears to have an unexpected benefit it turns dying tumor cells into a vaccine of sorts. The study demonstrated that NTP induces immunogenic cell death, a form of cell death that releases danger signals and tumor antigens, which in turn activates the body’s immune system. In syngeneic mouse models using TC-1 cells (engineered to express HPV oncoproteins), NTP treatment not only suppressed tumor growth but also increased the number of Tumor-Infiltrating Lymphocytes (TILs) a key indicator of immune activation.

The implications of this are far-reaching. Cervical cancer often creates a highly immunosuppressive microenvironment, which allows tumors to grow unchecked. If NTP can not only eliminate cancer cells but also reprogram the tumor microenvironment to promote immune surveillance, it may reduce recurrence rates and even enable immune system memory against the tumor.

The study also investigated the depth of NTP penetration in human cervical tissue, an essential factor for treating both micro invasive and small visible tumors. The results were promising: NTP achieved a penetration depth of approximately 5 mm in the cervical transformation zone, the most common origin site for cervical cancer. This finding reinforces NTP’s potential as a drug delivery enhancer, capable of delivering localized treatment deep into tissues without the need for incisions or thermal damage.

While the preclinical results are encouraging, several hurdles remain before NTP can become a mainstream option in cervical cancer care. First, more extensive clinical trials are needed to validate these findings and establish optimal treatment protocols. The safety profile in humans must be thoroughly assessed, especially regarding repeated applications and long-term effects on reproductive function.

Second, standardization and regulatory approval of NTP devices and treatment settings will be crucial. Factors such as gas composition, power settings and exposure time need to be tightly controlled to ensure reproducibility and safety across diverse clinical settings.

Third, the role of biomarkers like SOD1 must be further refined. Integrating biomarker screening into clinical decision-making can enhance the precision of NTP therapy, but it also introduces complexity in diagnostics and patient selection that will require integration with current pathology workflows.

Lastly, the combination of NTP with existing therapies such as vaccines, immune checkpoint inhibitors, or targeted therapies offers a promising avenue that has yet to be fully explored. As cervical cancer is largely driven by viral oncogenes, combining immune-activating treatments like NTP with immunotherapies could yield synergistic effects.

Conclusion

This research introduces a paradigm shift moving from radical, anatomy-altering surgeries toward targeted, immune-supportive and organ-preserving therapies. For young women facing cervical cancer, the possibility of effective treatment without sacrificing fertility is more than a medical milestone it is a restoration of hope and quality of life.